Launch
FDA approves amivantamab-vmjw with carboplatin and pemetrexed for non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations
What's New: Drugs RSS Feed · By FDA ·
The Brief
- On September 19, 2024, the FDA approved amivantamab-vmjw (Rybrevant, Janssen Biotech) with carboplatin and pemetrexed.
- The approval covers adults with locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations.
- The source is an FDA Drugs RSS item dated 2026-11-07 that reports the 2024 approval.
Why it matters
It adds a targeted antibody option to standard chemotherapy for a defined EGFR-mutant lung cancer population, which matters for oncology researchers and clinicians tracking treatment regimens.
Who’s affected
- Adults with locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations
- #oncology
- #lung cancer
- #egfr
- #fda approval
- #targeted therapy
- #amivantamab
On September 19, 2024, the FDA approved amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) with carboplatin and pemetrexed for adult patients with locally advanced or metastatic non-small cell lung cancer.
Timeline
FDA approves amivantamab-vmjw with carboplatin and pemetrexed for EGFR exon 19 deletion or L858R non-small cell lung cancer
What's New: Drugs RSS Feed
FDA approves amivantamab-vmjw with carboplatin and pemetrexed for non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations